Naltrexone Pill

ApprovedSmall molecule

YYale University

Naltrexone Pill is one of 200 small molecule programs targeting Eating Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

199

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eating DisorderActive, not recruiting

HypoglycemiaActive, not recruiting

PsoriasisActive, not recruiting

FibromyalgiaActive, not recruiting

Bipolar DisorderActive, not recruiting

Alcohol DrinkingActive, not recruiting

Eating DisorderPreclinical

Active, not recruiting

HypoglycemiaPreclinical

Active, not recruiting

PsoriasisPhase 1

Active, not recruiting

FibromyalgiaPhase 2

Active, not recruiting

Bipolar DisorderApproved

Active, not recruiting

Alcohol DrinkingPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Naltrexone Pill

YYale University

Approved

1 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Bimzelx

UCB

Preclinical

17 5

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 6

Raptiva

Roche

Preclinical

10 7

Siliq

BBausch Health Americas, Inc.

Preclinical

14 8

Victoza

Novo Nordisk

Preclinical

2 9

Lovenox

Sanofi

Preclinical

1 10

Olux

HHarrow Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Recruiting

Bariatric Surgery

NCT04599478

Q2 2027

Phase 2/3Active, not recruiting

Maintenance Treatment

NCT04605081

Q1 2028

Phase 2/3Recruiting

Bariatric Surgery

NCT05157698

Phase 3Recruiting

Alcohol Use Disorder

NCT05827159

Q4 2028

Phase 2Recruiting

Ketamine

NCT05940324

Clinical

Trials by Indication[1]

Alcohol Use Disorder2 trials

Emergency Department-Initiated Medications for Alcohol Use Disorder

Recruiting·YYale University·Phase 3·NCT05827159·240 enrolled

Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder

Completed·—·Phase 2/3·NCT05093296·62 enrolled

Eating Disorder2 trials

Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

Completed·YYale University·N/A·NCT02317744·22 enrolled

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

Completed·YYale University·Phase 2/3·NCT03946111·3 enrolled

Bariatric Surgery2 trials

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

Recruiting·YYale University·Phase 2/3·NCT04599478·160 enrolled

Pharmacological and Behavioral Treatment After Bariatric Surgery

Recruiting·YYale University·Phase 2/3·NCT05157698·160 enrolled

Altitude1 trial

Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude

Completed·VVA Loma Linda Health Care System·Phase 4·NCT05037032·16 enrolled

Fibromyalgia1 trial

Fibromyalgia and Naltrexone: The FINAL Study

Completed·OOdense University Hospital·Phase 2·NCT04270877·99 enrolled

7 more indications

Ketamine1 trial

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

Recruiting·SStanford University·Phase 2·NCT05940324·150 enrolled

Psoriasis1 trial

Efficacy of Low Dose Naltrexone in Psoriasis

Completed·JJinnah Postgraduate Medical Centre·Phase 1·NCT04250792·42 enrolled

Hypoglycemia1 trial

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

Completed·YYale University·N/A·NCT01462227·17 enrolled

Bipolar Disorder1 trial

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Recruiting·MMayo Clinic·Phase 4·NCT07213466·100 enrolled

Alcohol Drinking1 trial

Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

Completed·YYale University·Phase 2·NCT01519063·75 enrolled

Maintenance Treatment1 trial

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Active, not recruiting·YYale University·Phase 2/3·NCT04605081·100 enrolled

Unspecified1 trial

Bridging ED to Outpatient AUD Therapy With Naltrexone

Unknown status·AAlbert Einstein Healthcare Network·Phase 4·NCT05228418·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Naltrexone Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Naltrexone Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Naltrexone Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: YYale University

Naltrexone Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Alcohol Use Disorder2 trials

Eating Disorder2 trials

Bariatric Surgery2 trials

Altitude1 trial

Fibromyalgia1 trial

Ketamine1 trial

Psoriasis1 trial

Hypoglycemia1 trial

Bipolar Disorder1 trial

Alcohol Drinking1 trial

Maintenance Treatment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News